1	IN THE UNITED STATES DISTRICT COURT
2	FOR THE DISTRICT OF SOUTH CAROLINA CHARLESTON DIVISION
3	IN RE: LIPITOR : 2:14 MN 2502
4	IN NE. HIFTION . Z.14 PIN ZJOZ
5	
6	Status Conference in the above-captioned matter
7	held on Thursday, August 13, 2015, commencing at 3:07 p.m.,
8	before the Honorable Richard M. Gergel, in Courtroom III,
9	United States Courthouse, 83 Meeting Street, Charleston,
10	South Carolina, 29401.
11	
12	
13	APPEARANCES
14	
15	APPEARED FOR PLAINTIFFS:
16	Mark C. Tanenbaum, Esquire Blair H. Hahn, Esquire
17	APPEARED FOR DEFENDANTS:
18	Michael T. Cole, Esquire
19	Mark S. Cheffo, Esquire (via telephone) Amanda Kitts, Esquire
20	
21	
22	
23	REPORTED BY DEBRA LEE POTOCKI, RMR, RDR, CRR Official Reporter for the U.S. District Court
24 25	P.O. Box 835 Charleston, SC 29402 843/723-2208

1 THE COURT: Are we on the telephone here? 2 THE CLERK: Yes, sir. Good. We are having a status conference 3 THE COURT: 4 in the matter of In Re: Lipitor, 2:14-2502. 5 Could counsel who will be speaking during the hearing 6 today identify themselves for the record. 7 MR. HAHN: Blair Hahn for plaintiffs. 8 MR. TANENBAUM: Your Honor, I may address a few 9 questions; Mark Tanenbaum for the plaintiffs. 10 MR. COLE: Mike Cole for Pfizer, and Mark Cheffo is 11 on the phone, Your Honor. 12 THE COURT: Very good. Mr. Cheffo, we'll miss you, 13 but I'm sure you're in a better place than we are right now. 14 MR. CHEFFO: Good afternoon, Your Honor. Thanks for 15 indulging me today, I know we have some discrete issues on, 16 and I appreciate you giving me the opportunity to participate 17 by phone today. 18 THE COURT: Glad to do it. 19 Who wants to raise -- some of you have some issues you'd 20 like to raise? 21 MR. HAHN: Yes, sir, Your Honor. We have two issues 2.2. today just before you generally. One is the jury 23 questionnaire issues that Mr. Tanenbaum is going to address, 24 and the other is the deposition designation issue, which is a 25 little bit more complex issue, I think, that I'm going to

address with the Court.

1.3

If it please Your Honor, we have three objections and concerns with the defendant's proposal.

THE COURT: Which proposal; because we have two issues.

MR. HAHN: We have two big issues, but the defendants -- I'm sorry -- dealing with deposition designations.

THE COURT: Very good.

MR. HAHN: We have three objections. Pfizer's first paragraph in their letter to the Court dealing with deposition designations indicates in footnote one that they anticipate that they will be, quote, "a little late," unquote, on some of their disclosures. That theme continues when Pfizer states its proposal is intended to reflect the likelihood that Pfizer will change its deposition designations during trial.

Accordingly, the plaintiffs are concerned, as is evidenced by the multiple savings clauses throughout Pfizer's submission, that Pfizer does not intend to meet the extremely compressed time schedule that they propose.

We need real deadlines, Your Honor, that can be adhered to, absent good cause shown. And so for those reasons, we object to their proposal on the 96 hours and 48 hours and 24 hours.

Our second issue, Judge, is the order in which deposition

2.2.

designations are played. Pfizer's assertion that its proposal will limit the volume of deposition designations is not evidenced by its own actions in prior trials. To the contrary, I spoke with Rich Lewis this morning, he is lead counsel in the Hines matter in the Federal Court in West Virginia, and it was his stipulation that Pfizer attached to their brief to the Court. In the Hines matter, the plaintiffs' lead epidemiologist was deposed for three full days. Plaintiffs designated one hour of testimony. Pfizer designated five hours of testimony. And in the Hines matter they were forced to play six full hours of deposition testimony in their case in chief, as if they were sponsoring all six hours of testimony.

This served Pfizer's purpose, I would suggest to you, of confusing and boring the jury, as well as hiding key testimony for the plaintiffs in hours of nonrelated testimony.

Pfizer points to the Manual for Complex Litigation as authority for its position. However, Pfizer has cut the quote of the authors short, excluding the second half of the sentence. The full sentence, Your Honor, states that, "Portions of depositions usually will be introduced at trial in the same sequence in which they appear in the deposition..." That's where Pfizer stopped. The sentence continues. "...although another sequence can be adopted to improve comprehension."

I suggest to the Court the most important part of the Manual's teachings is what was left out by Pfizer, to improve comprehension to the jury of the testimony.

This can only be done by playing each party's designation separately, so that each party's position can be clearly understood by the jury. The only exception, of course, would be that set forth in U.S. v. Pintar, which we cited in our papers, which is to complete a verbal statement and not cut statements short.

Finally, Judge, we object to Pfizer's proposal for a color-coded chart to submit deposition designations to the Court. We see that will only serve to color Pfizer's position in a light most favorable to Pfizer. We would prefer the process either be agreed to by the parties or approved and provided to us by the Court.

THE COURT: Okay.

1.3

2.2.

MR. HAHN: Thank you, Judge.

THE COURT: Who wants to argue for defendant?

MR. CHEFFO: Your Honor, I'll address this point, if I might. So I think there, as I hear it and understand it with respect to depositions, Your Honor, there are two issues. First is how they'll be used in terms of the order, and I think the second is the process, Mr. Hahn's addressed the process; I guess I'll address that first.

I think to the extent that there was any confusion about

some of the language in our letter about deadlines, to be clear, the point here is not that we don't intend to deal with deadlines. Both sides, frankly, take the deadlines very seriously and have; we always will. I think what we were trying to anticipate was a concern, frankly, by the plaintiffs or either party that this would — or Your Honor, that this would somehow be a gotcha. That if somebody, in the middle of trial, was 45 minutes late or an hour, that, you know, understanding your Court's guidance that the rule of reason should apply, that that's the point of what we're raising. I mean, to the extent we want to have hard and fast deadlines, of course we will adhere to those, but it was really just in the spirit of professionalism that we wanted to put that in. It wasn't an effort to kind of have these fluffy nonmeaning deadlines.

The second, you know, and I think really what -- on this process issue it's really important, because I think it's an effort, and certainly Your Honor has never shied away from taking on and helping us and facilitating us with kind of working through all the issues pretrial, but this is a process that is not new here. What we're really basically saying is from experience we know the parties, because they haven't seen all the evidence, they designate a lot of information initially. To have the Court or any court kind of go through each one of those designations early on, before having some

context, having the parties understand what's going to actually be used, is really inefficient, and it places kind of an unfair burden on the Court when, in our experience, and I think the plaintiffs' as well, the vast majority of things that are designated pretrial ultimately get cut.

So our practice is really nothing more than an effort for the plaintiffs, once they — you know, 96 hours before, they say here's what we're really thinking about using; we, within 24 hours, respond. And then it gives the Court 48 hours to issue rulings that ultimately are going to be required, as opposed to essentially a lot of kind of make work for the parties and the Court.

So frankly, what we, in our proposal, we had said we will do all the objections and counter designations on everything, so that to the extent that there is a need for either Your Honor wants to hear something or see something, or the plaintiffs need rulings on certain issues for openings or whatever, we have some flexibility there. So really the whole point of our proposal was to be efficient with kind of the Court's time, in asking Your Honor to rule on things that ultimately matter.

The second point is really the process of how these things are played. And I think there's no dispute here that this is discretionary. You know, I think we're not citing the Manual or prior experience to say that Your Honor has no input or has

to do it one way or the other. You can do this either way. We think, though, even with the passage that Mr. Hahn just read, it basically says that, you know, what we should be doing is taking the depositions as they have been taken. And some of the irony, a lot of what the plaintiffs are talking about here are depositions that they took. So to the extent that they're concerned about, you know, not having questions put before the jury in the first part of their deposition, that seems to be incongruous with what they're saying about having the entire story put before the jury.

And I would also add that, you know, as Your Honor knows, from setting the rules, other than, I think, maybe one or two depositions, there has been no deposition that is more than seven hours. So the idea that there's these three-day depositions and people are going to have eight hours, I think you have sophisticated counsel on both sides.

So the process of having an orderly sequence where that's what we're proposing, you basically designate in the order of the deposition throughout, is something that we think kind of makes most sense from a process perspective.

And the last thing I would just say, Your Honor, is to the extent you have a different view, and again, we'll be guided by how you think ultimately is most efficient here, to the extent that you are going to allow them to first designate and then us designate, we would, one, just ask that Your Honor

have the rule of optional completeness, so even within their designations, they have to be complete. But again, I think that weighs in favor of having everything read the first time. Because then, frankly, the parties get into this back and forth, well, did you cut that off, does this sentence two paragraphs down the road -- I mean, Your Honor has been through this before, I'm sure, many times -- does that relate.

So to avoid all of those problems and all those issues, we think the most efficient way, the Manual supports it, is to basically have all of the designations done kind of in the page and in the line as they were taken in the deposition. So that it's going to work, you know, goose/gander for both sides.

THE COURT: Okay. Anything else --

MR. CHEFFO: Your Honor --

THE COURT: Yes.

MR. CHEFFO: I'm sorry. I'm a little surprised at the objection to the color-coded chart, but if the plaintiffs feel strongly about that and have a different way of presenting it to the Court, we're obviously happy to talk about that. It was not — they could even pick the color. It was nothing more than saying here's where we agree, you know, green, here's where the plaintiffs' positions and objections, and here's where we are. It's the way we've done it many many times before. But that's something I suppose either Your

1.3

Honor may have a preference of how we do it, or you could send us back to the drawing board about a way that we can agree on.

THE COURT: Okay. Well, Mr. Hahn, anything else you want to add?

MR. HAHN: Judge, I don't think that Mr. Cheffo or the Court wants me to pick the color of the chart.

MR. TANENBAUM: Blue for the plaintiffs, Your Honor, blue for the plaintiffs.

THE COURT: Folks, let me say here that we have a lot of issues swirling around here that I think really go to having some order and control in this trial. And it concerns me that each party, when they're putting up their case, by and large, with some limitations, ought to be the master of their own case. And clearly the Federal Rules do not anticipate that when you try to designate something, the other side gets to take over that party's presentation. That's, as they say, good for the goose, good for the gander; nobody should be able to do that.

I want to refer y'all to two sections, one in the Federal Rules of Civil Procedure and the other one the Federal Rules of Evidence, and I think are very relevant to this. Y'all cite me to the Manual for Complex Litigation, certainly important to consider, but it's really kind of basic. One is Rule 32(a)(6). "If a parties offers in evidence only part of a deposition, an adverse party may require the offeror to

introduce other parts that, in fairness, should be considered with the part introduced."

So to the extent it's confusing, it is misleading, and you need this additional --

(Brief interruption in proceedings.)

1.3

2.2.

THE COURT: Let me just go back, and if I repeat a little bit, that's okay. I think everybody's sort of focusing on the Manual for Complex Litigation. And there's a really basic provision of the Federal Rules of Civil Procedure, and a complimentary rule in the Federal Rules of Evidence that deal with this issue. Says, "If a party offers in evidence only part of a deposition, an adverse party may require the offeror to introduce other parts that, in fairness, should be considered with the part introduced."

Now, there's a complimentary provision in Rule 106 of the Federal Rules of Evidence.

I interpret that to mean that if somebody offers something -- you know, we're talking here, you know, on every ruling I've got to deal with how it may arise at trial, which may arise in a way that makes us think differently about this. But the general situation I'm thinking about is plaintiff offers the selection of a party opponent on a point. And to the extent that the point is made that is explained later in the deposition, I don't care where in the deposition it is explained, that ought to be included there to make the

testimony fairly represented, that's fine. But it doesn't suggest you then turn off and turn loose for hours of depositions of the deposition of testimony just because that person's testimony on that general subject. It's to promote clarity.

Now, it also goes on to say, in Federal Rule 32(a)(6), that, "Any party may, itself, introduce any other parts in their own case." They can do that in their own case. So if you open the door by using part of the deposition, they can then, in their case, even though it may not, in all fairness, be required, they can still -- you've opened the door and they may be able to use it for something else.

So the answer to that question is -- and I've got to control this trial, and I'm not letting one party, you know, basically pile on, at their whim, in somebody else's case, long hours of deposition.

Let me say this, folks. On Rule 403 I can control this trial. I'm not going to let anybody confuse the jury and bore the jury to death. Rule 403 is designed to prevent that from happening, and I intend that, to exercise that control.

So to sort of bring it down to a practical point, if you publish something of a party opponent that makes a point, if they further explained that particular point, fine, we're going to put that -- we'll allow that to be read right after or played right after that testimony. Because otherwise it's

2.2.

not fair. It's misleading to the jury. But we're not unleashing widespread testimony on general issues in the other party's case. And that applies to both parties. So to that issue, read those rules. It's a very circumscribed circumstance where you get to require someone else to introduce other parts. It's got to be a determination that in fairness it should be considered. And I read that as a rather narrow limitation, not an open door to then publish the party's deposition.

Now, in terms of the deadlines on designation, we have those for a reason, because otherwise we have chaos. And of course, if testimony comes up in a way in which there's good cause that something wasn't designated, we're going to be flexible about that. The first party that tries to jam the other is going to have it happen to them in about ten minutes. We're going to be flexible about it, but we're going to keep the deadlines we have, because otherwise we have roiling chaos, is what we have at trial, and it's just not practical.

The ruling is going to be those deadlines matter, but to the extent something wasn't designated and it was understandable why it wasn't designated, and something has come up that needs to be addressed, we're not going to have, as Mr. Cheffo described it, a gotcha moment. We're going to allow that. But that's not a daily, hourly thing that's going to be happening, it's going to happen from time to time and

we'll be flexible about that.

But those deadlines are there for a purpose, a really good purpose, that you guys kind of know what's coming. And if you keep roiling new designations, there's no way y'all can ever figure it all out. It's complicated enough as it is.

So that's my ruling. The deadlines matter. We're going to follow Federal Rule 32(a)(6) and Rule 106. And I read that to be a rather narrow circumstance under which counter designations are provided. Okay?

MR. HAHN: Thank you, Judge.

THE COURT: Let's go to this issue of the additional questions for our prospective jurors, our jury venire.

Let me just say something to y'all generally about this. I do not seek to be your mouthpiece to make your closing argument, or to ask for lots of damages for the plaintiff or a defense verdict. That's for y'all. Y'all are really good at that. You don't need me to do that. And I resist the request that I use voir dire or anything else, opening and closing charges as well, to be y'all's closing argument. And you'll see when you make proposals to me that I'm constantly scratching it out, if it's nothing more, I want to be a neutral presenter of the law. And the jurors —— I'm not going to comment on the facts, that's the British system, not the American system. And you guys can comment to your heart's content in your argument.

2.2.

So understanding sort of my inclination that I don't want to be a mouthpiece for anyone, let's now look at the plaintiffs' proposals, because, frankly, a number of these I felt like y'all were trying to make me y'all's ventriloquist, y'all were -- I was the puppet and y'all were the puppeteer.

First of all, question one, I think the -- I would rephrase that. I think it's substantively something everybody would be worthwhile to have, and I wouldn't want to ask it live, because it's very invasive of people's privacy and so forth. But I would say something, have you or any member of your immediate family, parentheses, spouse, children, parents, et cetera, immediate family, been diagnosed with any of the following. And then we have you, and then any immediate family member. I want to define it, I don't want to hear about third cousins having a heart attack. We want to know about the immediate family. And I think that one is fine.

Questions two and three, do you or does any immediate family member take a drug to lower cholesterol. We probably ought to somehow combine that into one question. And you have in number three, write "unknown" if you don't know, but you didn't do that for number two. I think we need to know either way if they're on a statin. I think that's something worth knowing.

Questions four through nine, I felt like you were asking me to be the puppet for y'all on damages, and I declined the

honor of doing that. Y'all make your own argument about damages to the jury. So four through nine are out.

Number ten, I didn't exactly like it the way either party -- defendant also asked me a question, but I think similar to this, I think the -- it's an important issue, and that is, is a jury -- if you've got an individual on one side and a pharmaceutical company on the other, can you be fair. Either way. Can you be fair.

So I looked back at what my standard questionnaire is, and this is the question I would have there. Do you feel that you can be fair to both sides in a lawsuit that involves an individual on one side and a pharmaceutical company on the other. Okay? Everybody -- I mean, that's the question. And if somebody says, Your Honor, I don't think I can because my daughter works for a pharmaceutical company, fine. If they say I can't do it because I hate big corporations, fine, we know all that. That's what we want to know. We want unbiased jurors.

So I think that gets to it both -- questions one through three kind of went -- of the defendant's questions went to that, and I think that's a more neutral way to ask that question, not suggesting one side or the other.

Question 11, which asks, do you have any training or experience in the following areas. We actually asked that, questions three and seven through ten pretty much give you

that information in the standard questionnaire, and I don't think we need more, I think it's duplicative. And in some ways you start asking that specific, you're kind of driving perhaps some points. And I think the more neutral question is — and it's asked in the standard questionnaire — things like where do you work, what training do you have, where does your spouse work. I mean, we're getting to that information in a less direct way, but we're still getting to that information.

So in the end, you know, I like question one, questions two and three of the plaintiff. I mentioned how we would change number ten.

Then for the defendants, questions one through three are pretty much caught up in that revised question ten of the plaintiffs about being fair to a pharmaceutical company.

Question four is, have you ever developed a serious side effect from a drug that you were not warned about, I think that's a fair question and I think both sides ought to know that.

And question five is captured in question one, the way we described it, in which we will know who has elevated -- you know, who has been diagnosed with these conditions. Okay?

So I think that's kind of giving us -- and we will also ask a question -- we're working, Miss Boroughs and I are working on this now -- is to say who has a problem, serious

problem with being a juror for a number of weeks. We need to kind of know that. My juror folks in Columbia are calling a large number of prospective jurors. And the reason is we just think there are not a lot of people who can sit around for a month. I mean, I'm going to tell you, if somebody stands up and says, Your Honor, if I do this, I will be bankrupt, my business will be closed, I'm not putting them on a jury. You don't want them on a jury. They're going to be so distracted and upset about sitting there that you don't want them anyway. And I want to see what kind of jurors we get. I don't think it's -- you know, sometimes they say when you do long trials you get nothing but senior citizens, and we'll have 100 percent of the people on statins, if we do that. I'm going to certainly want some diversity of ages and all of that.

But we will ask a question, and I'm going to ask y'all today in just a minute, have we made any reassessment about the length of time, because I want to tell the jurors, give them an idea about what would be the expected time. I want to put that in the jury notice, or we'll ask a question about that.

Okay. Y'all have heard my thoughts. Does anyone have any real heartburn about that? First from the plaintiff.

 $$\operatorname{MR}.$$ TANENBAUM: I think I did a great job arguing that, Your Honor.

THE COURT: From the defendant?

2.2.

MR. COLE: No, Your Honor, I had all these great arguments, but you've already captured them all, so we're good.

MR. HAHN: Your Honor, do you want the parties to submit new questions?

THE COURT: No, we've got it under control. Guys, I get this like, you know, 15 times every two months I have to go through this.

MR. TANENBAUM: Just so you'll know, the questions that we had originally that the defense complained about, we sent back 36, all came from an 85-question agreed to questionnaire that Pfizer was a party to. So that is how that all blew up --

THE COURT: That's okay, but you know, if you figure out where our standard questionnaire came from, it came from Judge Joe Anderson, okay, who is our most thoughtful judge in terms of figuring standard practices, he's been on the Manual for preparation of the Trial Manual for District Judges. He's very thoughtful about this. And we all use it. And it is — he's tweaked it over the years; it is really good. I mean, I have people who have come from other places say that is the best questionnaire they have ever seen. And I don't take any pride in the authorship because I didn't author it, Judge Anderson did.

But in situations like this, there are circumstances where it is certainly appropriate to ask additional questions. And I'll be honest with y'all, I'm surprised I don't get this request more often. I mean, I really am. Why I don't get — because in many cases there are very particularized pieces of information not captured, and which would be highly probative. But we're so rarely asked, that my juror coordinator in Columbia had to — it was like a big deal, you know, to be asking something, which I think I would expect it to be and probably should be more commonly done. But notwithstanding the excellent nature of the questionnaire, it's just not tailored to individual cases.

I was asked by my court people to ask, are y'all going to seek daily transcripts?

MR. HAHN: Yes, sir, Your Honor.

THE COURT: Okay. That's good to know. Will y'all seek sequestering of your witnesses?

MR. TANENBAUM: I hadn't thought about that yet, Your Honor, just -- we had a list of things that we were going raise, but we've talked about waiting and coming back. Could we put our heads together and meet?

THE COURT: That's fine. Let me tell you why, you know, number one, obviously before the trial we need to know that. And if either party requests it, it's done, under Rule 615 it's done. I raise it in conjunction with the trial

1.3

daily transcripts is I want to make it clear you can't be showing the transcripts to your future witnesses. Okay? I mean, that's very important here. Because if you're going to do it, it really complicates things. And I find myself having to warn parties about that. I mean, I can understand the benefit of getting daily transcripts, but there are limits on their use, and one of them is you can't prepare witnesses by providing them the information.

MR. COLE: Your Honor, we talked earlier today about requesting a future meeting with you to sort of talk about these nuts and bolts kind of things. And I think the plaintiffs have got some issues, we've got some issues, we'd probably like to have the lawyers that are going to be trying the case involved in that discussion. And it might be helpful that if you have things like that, how long the trial is going to be, are you going to sequester the witnesses, some questions you need us to get back to you about, we would go back and talk about it.

THE COURT: Let me tell you, the length of trial we need to know fairly soon because we have to send out our questionnaire.

MR. TANENBAUM: I can tell you that there are 45 witnesses who have been deposed in this case, so --

THE COURT: Hopefully that will give you good quidance that you don't need 45 testifying.

MR. TANENBAUM: Each side has eight liability, general liability experts. We've got --

1.3

2.2.

THE COURT: Are you going to call -- I mean, folks, to the extent they're going to say the same thing, I'm going to exercise my control over this trial. I'm not going to allow you to put up repeated experts who basically say the same thing.

MR. TANENBAUM: They each have different areas, Your Honor.

THE COURT: That's fine, but y'all might --

MR. CHEFFO: Your Honor?

THE COURT: Yes, Mr. Cheffo.

MR. CHEFFO: I'm sorry, Your Honor, I didn't mean to interrupt you. I was going to say it is something we probably should talk about, maybe won't agree, but to the extent that we use our experience as a guide, that's all we can ever do. I mean, in the Zoloft litigation, which I've talked about a little bit, we had similar documents, lots of witnesses, and in those cases, and I think initial projections of four and six weeks, the two trials that have taken place have been, I think, about 12 to 14 days total. So, you know, our view at the end of the day, with kind of good lawyers and understanding that Your Honor's going to control the courtroom and that no one wants to bore juries with repetitive testimony, I think it would be much closer to a two-, perhaps

three-week trial than longer than that, based on the issues here.

THE COURT: Let me ask you this.

2.2.

MR. CHEFFO: Particularly the general causation witnesses are not all going to come to trial.

THE COURT: Let me ask you this. If I tell the jurors that the outside is four weeks, is that safe?

MR. TANENBAUM: I think that's safe, Your Honor.

THE COURT: So what we'll do is we'll say this trial starts on November X, whatever day that is, and it will be a trial, and it could go till December or whatever the date is, we'll figure out, does that present a problem. And let me say, don't be surprised I have a lot of returns, because that's, of course, over Thanksgiving.

MR. TANENBAUM: Just to say one thing. We've been meeting regularly preparing already, as you would expect. My gut feeling is when I put a witness up on direct, even an expert, two hours is a long time. Cross-examination generally can take, from our perspective — it just depends on how long the cross-examination would be. But I don't anticipate longer than two, perhaps three hours on direct examination with these experts.

I also told Mr. Cheffo and Mr. Cole that I wasn't prepared to be bound by it, but I thought, based on the timeline that we've put together, while there are 5000 hot documents, so to

speak, out of 5 million or whatever it is, I'm thinking about 150 to 200 at most. I mean, I've seen juries, not in my case, go to sleep, and I just don't --

THE COURT: I'm going to be honest with you. If you put up repetitive witnesses with a direct of two or three hours, they will not hear much of that testimony. I mean, just warning y'all. Because you take a two- or three-hour direct, you're talking about taking up basically a half day of testimony for a jury. And then you get up, and you go one witness a day for awhile, you will have lost your jury. I'm going to tell you. And that is not good for either party.

MR. TANENBAUM: Right. So I just say that for the outside. I'm reminded always, I say this all the time about Mark Twain, "I would have written a shorter letter, but I didn't have enough time." So that's my view of how you do these things. I don't think there's any difference from theirs.

THE COURT: I mean, y'all know in the end, though you might have all these experts make all these points, that part of the skill of presenting a case is to home in on a few points and drive them home. The jury can't absorb the 16 different arguments, okay? There are going to be two or three arguments on each side, and you've got to drive those home. That's what effective trial is. And if you just throw it up, everything against a wall and hoping something sticks, usually

it doesn't, it all goes off, just doesn't work.

2.2.

So I'm not going to tell y'all how to try the case. I'm concerned that my jurors not be bored, not be burdened with unnecessary repetition. And that I'm hoping y'all will talk to your experts about speaking English. Okay? As opposed to medicalese which they love to get in and talk in acronyms and terms eight-syllable words, nobody knows what they mean. And after awhile, the jury's just staring at the sky. I mean, this is necessarily a somewhat complicated issue on the medicine, but good lawyers can explain it in a simple enough language that people without advanced medical degrees can understand it. You've got to, because that's who's going to be on your jury. You don't get a bunch of Harvard professors who are going to be hearing this case.

MR. TANENBAUM: Yes, sir.

THE COURT: So we will say a couple of -- We'll say four weeks.

MR. CHEFFO: Sounds like we're out again?

THE COURT: Hold on just a second.

(Discussion held off the record.)

THE COURT: Folks, I wanted to tell y'all when we're sitting here looking at the calendar figuring out days for the pretrial, we're going to have to compress, just by a few days, a few of the schedules to get everything in, and we'll be issuing a modified order that just very slightly, not, I don't

2.2.

think, any great way, compresses a couple of different things, just so on the Wednesday before trial I can have a pretrial, and we're not doing it on Friday morning, if something comes up, nobody has any opportunity to really address it. So we'll be issuing that in the next few days.

Now, are there additional matters for the Court to address that haven't been addressed here? First from the plaintiff.

MR. HAHN: Your Honor, if we could look on your calendar for a date late August, I know you have a vacation coming up, but after that, where we could come and perhaps talk in chambers about these housekeeping issues?

THE COURT: Yeah. I don't have my calendar in front of me. Let me give you my schedule. The last week of August I start a trial, criminal trial, and they tell me it will take all week. I have got my doubts about that, but that's what they're telling me. And I think we draw juries in about the Tuesday -- first Tuesday in September? September 1st. So why don't y'all talk to Miss Boroughs here about proposed dates that work with y'all, and we'll try to match it up. I think we have between now and your trial, seven trials set. Plus, I've got y'all's general Daubert and case-specific Daubert. And, Mr. Hahn, some of your partners were -- I guess some of your -- not your partners, but counsel from firms that are in your group were mad at me; they wanted to do a patent trial ahead of your bellwether trial. And I had to explain the fact

2

3

4

5

6

7

8

9

10

11

12

1.3

14

15

16

17

18

19

20

21

2.2.

23

24

25

```
that they had filed eight separate Daubert motions, made it
somewhat difficult for me to get to those, in the face of what
I'm looking at between now and November.
    (Discussion held off the record.)
         THE COURT: Any other issues from the plaintiff,
anything else I need to address?
         MR. HAHN: No, sir, Your Honor.
         THE COURT: From defense?
         MR. COLE: We're fine, Your Honor.
         THE COURT: What we may try to do, and Miss Boroughs
will work with us, maybe toward the end of that week of
August 24, anticipating that the thing really won't go the
whole week, we'll try to see about -- I have already been
having that assumption and putting some things there, but I'm
glad to try to accommodate y'all to get it done, okay?
    Anything further? So much for no meetings in August,
right? Anything from anyone? First of all, Mr. Cole, you
don't have anything?
         MR. COLE: No, Your Honor.
         THE COURT: Mr. Cheffo?
         MR. CHEFFO: No, Your Honor, thank you very much.
         THE COURT: Anyone else on the telephone need to
address any matters with the Court?
    (No response.)
    (Court adjourned at 3:48 p.m.)
```

REPORTER'S CERTIFICATION I, Debra L. Potocki, RMR, RDR, CRR, Official Court Reporter for the United States District Court for the District of South Carolina, hereby certify that the foregoing is a true and correct transcript of the stenographically recorded above proceedings. S/Debra L. Potocki Debra L. Potocki, RMR, RDR, CRR